Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Biomacromolecules ; 8(7): 2135-41, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17559263

ABSTRACT

Monodisperse stereocomplex nanogels were obtained through the self-assembly of an equimolar mixture of dextran-graft-poly(L-lactide) (Dex-g-PLLA) and dextran-graft-poly(D-lactide) (Dex-g-PDLA) amphiphilic copolymers with well-defined composition in a dilute aqueous solution. The stereocomplex nanogel possessed partially crystallized cores of hydrophobic polylactide (PLA) and the hydrophilic dextran skeleton by intra- and/or intermolecular self-assembly between PLLA and PDLA chains. The stereocomplex nanogels exhibited significantly lower critical aggregation concentration (CAC) value as well as stronger thermodynamic stability compared with those of the corresponding L- or D-isomer nanogels. The mean diameter of the stereocomplex nanogels was 70 nm with narrow size distribution, implying they were well-defined and presumably nanogels. Furthermore, stereocomplex nanogel exhibited strong kinetic stability. The tunable degradation properties of Dex-g-PLA nanogels were achieved by varying the number of grafted PLA chains as well as applying stereocomplexation. This study demonstrates the advantage of stereocomplexation in the design of biodegradable nanogels with enhanced stability.


Subject(s)
Dextrans/chemistry , Nanotechnology , Polyesters/chemistry , Microscopy, Atomic Force , Solutions , Water , X-Ray Diffraction
2.
J Cardiovasc Pharmacol ; 47(5): 629-35, 2006 May.
Article in English | MEDLINE | ID: mdl-16775500

ABSTRACT

Cardiac endothelial nitric oxide synthase (ecNOS) was suppressed and inducible NOS (iNOS) enhanced at the decompensated heart failure stage in 18-week-old Dahl salt-sensitive (DS) hypertensive rats to which a high-salt diet had been administered from the age of 6 weeks. Nicorandil (NIC) enhanced ecNOS by activating Adenosine triphosphate-sensitive potassium channels (K-ATP channels) in the normal rat left ventricle. In this study, left ventricular hypertrophy, remodeling, function, cardiac ecNOS, and iNOS were compared between NIC and isosorbide dinitrate (ISDN) treatments in DS hypertensive rats with congestive heart failure. We examined DS hypertensive rats of 18 weeks of age to which 8% NaCl had been administered from the age of 6 weeks, and to which subdepressor doses of NIC (6 mg/kg/d), ISDN (6 mg/kg/d), and vehicle (CON) were administered from the age of 11 weeks. Contractility (Ees), stiffness (Eed), left ventricular end-diastolic volume, and left ventricular end-systolic volume were measured by conductance catheter and micromanometer on the basis of the pressure-volume relationship, and mRNA and protein levels of ecNOS and iNOS in the left ventricle were measured by reverse transcription-polymerase chain reaction and Western blot analysis at 18 weeks. LV mass index and LV dimensions were smaller in the NIC and ISDN groups than in the CON group (P < 0.01), and the first parameter was lower in the NIC than in the ISDN group (P < 0.01). Ees was also better maintained in the NIC and ISDN groups than in the CON group (NIC: 3349 +/- 649; ISDN: 2950 +/- 577, P < 0.05 vs. NIC; CON: 1424 +/- 375 mL/mmHg, P < 0.01 vs. treatments). Eed was exacerbated only in the ISDN group. NIC enhanced whereas ISDN suppressed ecNOS mRNA and protein levels (NIC 2.0-fold and 1.8-fold, ISDN 0.70-fold and 0.8-fold vs. CON; P < 0.01, respectively). However, no intragroup differences in iNOS mRNA or protein levels were observed for the 3 groups. More significant improvements in cardiac function and LV hypertrophy regression were observed in an NIC group than in an ISDN group of DS hypertensive rats. Activation of the K-ATP channel seems to induce this beneficial effect, which may be mediated in part by enhanced ecNOS expression in the heart in DS hypertensive congestive heart failure rat model.


Subject(s)
Antihypertensive Agents/pharmacology , Heart Failure/drug therapy , Hypertension/drug therapy , Nicorandil/pharmacology , Nitric Oxide Synthase Type III/biosynthesis , Animals , Blood Pressure/drug effects , Cardiac Volume/drug effects , Heart Failure/metabolism , Heart Failure/physiopathology , Hypertension/metabolism , Hypertension/physiopathology , Isosorbide Dinitrate/pharmacology , Male , Nitric Oxide Donors/pharmacology , Nitric Oxide Synthase Type III/genetics , Potassium Channels/agonists , RNA, Messenger/biosynthesis , Rats , Rats, Inbred Dahl , Up-Regulation , Ventricular Remodeling/drug effects
3.
Cardiovasc Drugs Ther ; 18(1): 13-22, 2004 Jan.
Article in English | MEDLINE | ID: mdl-15115899

ABSTRACT

Nicorandil is an adenosine triphosphate sensitive K (K-ATP) channel opener and a nitric oxide donor. K-ATP channels and nitric oxide are important factors in ischemic preconditioning, which in turn suppresses reperfusion arrhythmias. The present study sought to evaluate whether nicorandil suppresses ischemic-induced ventricular arrhythmias and enhances sulfonylurea receptors (SUR 2; subunit of K-ATP channel), endothelial nitric oxide (eNOS), and inducible nitric oxide (iNOS) expression in the left ventricle after myocardial infarction without reperfusion. Thirty male Sprague-Dawley rats at 7 weeks of age were separated into three groups, as follows. Acute myocardial infarction was induced in twenty rats by ligating the left main coronary artery. Ten of these twenty rats were continuously administered nicorandil at 3 mg/kg/day i.p. The other ten rats were left untreated. The ten controls were untreated and sham-operated. After coronary ligation, ventricular arrhythmias were evaluated from stored ECG signals. At 24 hours after treatment, eNOS, iNOS, and SUR2 mRNA levels and eNOS, iNOS expression in the left ventricle were determined by reverse transcription polymerase chain reaction (RT-PCR) and by immunohistochemical staining, respectively. Nicorandil suppressed the total number of ventricular arrhythmias from 1 to 2 hours, the total duration of ventricular tachycardia from 2 to 3 hours, and that of ventricular fibrillation from 1 to 2 and from 4 to 5 hours after coronary ligation. Nicorandil improved the survival rate 24 hours after coronary ligation. Levels of SUR2 mRNA increased only in left ventricles treated with nicorandil, particularly in the non-ischemic myocardium. eNOS mRNA was enhanced 2.2-fold in the area at risk in infarcted controls compared to sham-operated rats. In the non-ischemic area and area at risk of rats treated with nicorandil compared to sham-operated rats, eNOS mRNA was enhanced 3.3- and 2.7-fold, respectively. Staining indicated that the highest concentrations of eNOS occurred in the endothelium and myocardium of the non-ischemic area of rats treated with nicorandil. iNOS mRNA was present in both the area at risk and the non-ischemic area only in infarcted rats, and levels thereof were higher in the area at risk than in the non-ischemic area. However, there was no difference in iNOS mRNA levels between nicorandil-treated rats and controls. iNOS exhibited stronger staining in the area at risk than in the non-ischemic area of both nicorandil-treated and infarcted controls, with no differences between these two groups of rats. The mechanisms of protection against lethal ventricular tachyarrhythmia in nicorandil may increase nitric oxide release by upregulated eNOS expression through the opening of K-ATP channels and/or a K-ATP channels opener itself after acute myocardial infarction.


Subject(s)
ATP-Binding Cassette Transporters/biosynthesis , Anti-Arrhythmia Agents/pharmacology , Arrhythmias, Cardiac/prevention & control , Myocardial Infarction/complications , Nicorandil/pharmacology , Nitric Oxide Synthase/biosynthesis , Potassium Channels, Inwardly Rectifying/biosynthesis , Potassium Channels/biosynthesis , RNA, Messenger/biosynthesis , Receptors, Drug/biosynthesis , ATP-Binding Cassette Transporters/genetics , Animals , Arrhythmias, Cardiac/etiology , Arrhythmias, Cardiac/mortality , Heart Ventricles/drug effects , Heart Ventricles/physiopathology , Male , Nitric Oxide Synthase/genetics , Nitric Oxide Synthase Type II , Nitric Oxide Synthase Type III , Polymerase Chain Reaction , Potassium Channels/genetics , Potassium Channels, Inwardly Rectifying/genetics , Rats , Rats, Sprague-Dawley , Receptors, Drug/genetics , Sulfonylurea Receptors , Up-Regulation
4.
Int J Cardiol ; 91(1): 25-35, 2003 Sep.
Article in English | MEDLINE | ID: mdl-12957726

ABSTRACT

OBJECTIVE: Our aim was to examine whether inducible nitric oxide synthase (iNOS) expression in the left ventricle (LV) is associated with deterioration of contractility of the failing heart. METHODS: Twenty male Dahl salt-resistant (DR) and 20 salt-sensitive (DS) rats were fed a high-salt diet starting at 6 weeks of age. Ten rats of each strain were studied at 11 or 18 weeks of age. The blood pressure, heart rate and LV mass were measured. The indices of systolic function (contractility; E(es)) and diastolic function (stiffness; E(ed)) were calculated from the end-systolic and end-diastolic pressure-volume relationships, respectively. The iNOS mRNA and protein levels in the LV were determined by reverse transcription-polymerase chain reaction and Western blot analysis. RESULTS: The blood pressure, heart rate and LV mass were greater in the DS rats than in DR rats (P<0.01, P<0.01, P<0.01). The E(es) was greater in the DS rats than in DR rats at 11 weeks (3355+/-1048 vs. 2404+/-248 mmHg/ml; P<0.01), but it was smaller in the DS rats than in DR rats at 18 weeks (1424+/-375 vs. 2092+/-751 mmHg/ml; P<0.01). The E(ed) was greater in DS rats than in DR rats at both ages. The iNOS mRNA and protein levels were elevated in the 18-week-old DS rats (P<0.01, P<0.01) but not in the 11-week-old DS rats, in comparison with those in the DR rats. CONCLUSIONS: Cardiac iNOS expression and nitric oxide production may have led to deterioration of systolic function from 11 to 18 weeks. iNOS may play an important role in the transition from compensated hypertrophy to failure.


Subject(s)
Heart Failure/physiopathology , Heart Ventricles/pathology , Nitric Oxide Synthase/metabolism , Ventricular Dysfunction, Left/physiopathology , Ventricular Remodeling , Animals , Cardiomegaly/complications , Cardiomegaly/physiopathology , Diastole , Heart Failure/etiology , Heart Failure/pathology , Hypertension/complications , Hypertension/physiopathology , Male , Myocardial Contraction/physiology , Organ Size , Rats , Rats, Inbred Dahl , Systole
5.
Hypertens Res ; 25(2): 211-9, 2002 Mar.
Article in English | MEDLINE | ID: mdl-12047037

ABSTRACT

We evaluated the protective effects of long-term treatment with betaxolol, a specific beta-antagonist, on platelet-derived growth factor (PDGF) A-chain and transforming growth factor (TGF)-beta1 gene expression in the left ventricle of Dahl salt-sensitive hypertensive rats fed a high-salt diet. In addition, we evaluated the relations between these effects and coronary microvascular remodeling, expression of extracellular signal-regulated kinases (ERK) belonging to one subfamily of mitogen-activated protein kinases, and expression of p70S6 kinase belonging to one subfamily of ribosomal S6 kinases. Betaxolol (0.9 mg/kg/day, subdepressor dose) was administered for 5 weeks, from 6 weeks of age to the left ventricular hypertrophy stage at 11 weeks of age. Increased PDGF A-chain and TGF-beta1 mRNA and protein expression were suppressed by betaxolol. Upregulated activities of ERK1/2 and p70S6 kinase phosphorylations were decreased by betaxolol. Betaxolol administration resulted in significant improvements in the wall-to-lumen ratio, perivascular fibrosis and myocardial fibrosis. Thus, we conclude that ERK1/2 and p70S6 kinase activities may play a key role in coronary microvascular remodeling of Dahl salt-sensitive hypertensive rats, and that beneficial effects of betaxolol on cardiovascular remodeling may be at least partially mediated by decreased PDGF A-chain and TGF-beta1 expression in the left ventricle.


Subject(s)
Adrenergic beta-Antagonists/therapeutic use , Betaxolol/therapeutic use , Hypertension/drug therapy , Hypertension/enzymology , Mitogen-Activated Protein Kinases/antagonists & inhibitors , Platelet-Derived Growth Factor/metabolism , Ribosomal Protein S6 Kinases, 70-kDa/antagonists & inhibitors , Transforming Growth Factor beta/metabolism , Animals , Body Weight/drug effects , Gene Expression/drug effects , Hemodynamics/drug effects , Hypertension/genetics , Hypertension/physiopathology , Male , Myocardium/metabolism , Myocardium/pathology , Organ Size , Phosphorylation/drug effects , Platelet-Derived Growth Factor/genetics , RNA, Messenger/metabolism , Rats , Rats, Inbred Dahl , Transforming Growth Factor beta/genetics , Transforming Growth Factor beta1
SELECTION OF CITATIONS
SEARCH DETAIL
...